logo
Share SHARE
FONT-SIZE Plus   Neg

MMRC And Synta Pharma Begin Ganetespib Clinical Trial In Multiple Myeloma

Synta Pharmaceuticals Corp. (SNTA) and the Multiple Myeloma Research Consortium or MMRC announced the start of a clinical trial evaluating ganetespib, a second generation Hsp90 inhibitor being developed by Synta Pharmaceuticals, as a single agent and in combination with the proteasome inhibitor bortezomib (VELCADE) for the treatment of relapsed multiple myeloma.

The trial, made possible by the funding up to $1 million by the Multiple Myeloma Research Foundation (MMRF), will be conducted through the MMRC. The MMRC is a consortium of sixteen world-renowned academic institutions and community centers whose mission is to accelerate the development of novel and combination treatments for patients with multiple myeloma by promoting and facilitating collaborative research between industry and academia.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Coca-Cola announced that it is removing its trademark logo from cans in the Middle East as part of the soda giant's marketing campaign to fight prejudice. The company has replaced its famous trademark logo with "Labels are for cans not people," message. The company has made the change during the... Carnival said it has obtained U.S. approval to begin cruises to Cuba. The announcement by the cruise operator follows the recent restoration of diplomatic relations between the U.S. and Cuba. GoPro has just launched a facile camera, its smallest and lightest yet, as the action-camera sports maker seeks to further entice its adventure-seeking consumers.
comments powered by Disqus
RELATED NEWS
Trade SNTA now with 
Follow RTT